Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,611 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement

NCT03242213
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mobile App
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Internet-Based Depression Screening for College Students

NCT01326793
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Skype Consultation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional

A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model

NCT05685758
View directory record Official record
Conditions
Depression, Depressive Disorder, Clinical Depression, Major Depressive Disorder
Interventions
FTP-based therapeutic mobile-app
Other
Lead sponsor
Hedonia Ltd
Industry
Eligibility
20 Years to 50 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

NCT01110889
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder

NCT06340958
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder (MDD)
Interventions
CLE-100, Placebo
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
La Jolla, California • Lafayette, California • Upland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

NCT01727726
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Brexpiprazole, Seroquel XR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression

NCT05118750
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 oral (PO) tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Culver City, California • Sacramento, California • Santee, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 7:27 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555
View directory record Official record
Conditions
Depression
Interventions
Placebo matching with BMS-820836, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
94
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 21, 2026, 7:27 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

NCT01263223
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

NCT01876823
View directory record Official record
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 1 Interventional

Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder

NCT00719979
View directory record Official record
Conditions
Depression
Interventions
Behavioral intervention (iCBT + TeleCoach), Internet-based cognitive behavioral therapy (I-CBT), Treatment as usual / Wait-list control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 21, 2026, 7:27 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

NCT07216404
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Unipolar Depression
Interventions
Biospecimen Collection, Counseling, Interview, Psilocybin, Survey Administration
Procedure · Other · Drug
Lead sponsor
Alan Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis

NCT02443584
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
pharmacogenetic testing
Other
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 21, 2026, 7:27 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

NCT03833206
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 7:27 AM EDT
Terminated Phase 4 Interventional

Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes

NCT00177424
View directory record Official record
Conditions
Cerebrovascular Accident, Depression
Interventions
sertraline, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 3 Interventional

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

NCT00415142
View directory record Official record
Conditions
Depressive Disorder
Interventions
saredutant (SR48968), placebo, escitalopram
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years to 64 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury

NCT03307070
View directory record Official record
Conditions
Major Depressive Disorder, Traumatic Brain Injury
Interventions
Cognitive Behavioral Therapy for individuals with TBI, Waitlist Control
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 4 Interventional

A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder

NCT00191061
View directory record Official record
Conditions
Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Little Rock, Arkansas • Coral Springs, Florida • Jacksonville, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional

Cognitive Training for Depression II

NCT01934491
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Training A, Cognitive Training B
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 7:27 AM EDT
Completed Not applicable Interventional Results available

Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder

NCT04770285
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CT-152 - Digital Therapeutic, Sham
Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
22 Years to 64 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 21, 2026, 7:27 AM EDT